Drug Profile


Alternative Names: copper-ATSM; diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator University of Melbourne
  • Developer Collaborative Medicinal Development; Procypra Therapeutics
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis
  • Preclinical Parkinson's disease

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Amyotrophic lateral sclerosis in Australia (PO) (NCT02870634)
  • 25 Aug 2016 Collaborative Medicinal Development plans a phase I trial in Amyotrophic lateral sclerosis in Australia (NCT02870634)
  • 24 Aug 2016 Preclinical trials in Amyotrophic lateral sclerosis in Australia (PO) (NCT02870634) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top